Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.37 |
| ▸ | ADH1C | P00326 | 3/20 | 0.37 |
| ▸ | ADH1A | P07327 | 3/20 | 0.37 |
| ▸ | ADH4 | P08319 | 2/20 | 0.37 |
| ▸ | ADH1B | P00325 | 2/20 | 0.36 |
| ▸ | ADH7 | P40394 | 2/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11114817 | 0.86 | TSHR (0.43) | TSHRFAAHTRPV1ALOX5EPHX1 | |
| SCHEMBL12513178 | 0.85 | TSHR (0.64) | TSHRFAAHTRPV1ALOX5EPHX1 | |
| SCHEMBL26444220 | 0.85 | TSHR (0.64) | TSHRFAAHTRPV1ALOX5EPHX1 | |
| SCHEMBL13963615 | 0.85 | TSHR (0.64) | TSHRFAAHTRPV1ALOX5EPHX1 | |
| SCHEMBL13396442 | 0.85 | TSHR (0.50) | TSHRFAAHTRPV1ADH1CADH1A | |
| SCHEMBL29559353 | 0.84 | EPHX1 (0.48) | TSHRALOX5EPHX1S1PR2S1PR4 | |
| SCHEMBL28380195 | 0.84 | EPHX1 (0.48) | TSHRALOX5EPHX1S1PR2S1PR4 | |
| SCHEMBL29385123 | 0.84 | EPHX1 (0.48) | TSHRALOX5EPHX1S1PR2S1PR4 | |
| SCHEMBL28249807 | 0.84 | EPHX1 (0.48) | TSHRALOX5EPHX1S1PR2S1PR4 | |
| SCHEMBL25611408 | 0.84 | TSHR (0.57) | TSHRFAAHTRPV1ALOX5EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724697-A | Arubiprostone isomerism Process for preparing bulk impurities | 江苏普润生物医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-112262130-B | Crystal modifier of ondoxicam | 阿尔比里奥公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-116457014-A | Mitochondrial biosynthesis and function enhancement by inhibition of prostaglandin degrading enzyme 15-PGDH | 莱兰斯坦福初级大学评议会 | 2023-07-18 | — | — | CN | disclosed |
| US-20170224667-A1 | CANCER CHEMOPREVENTIVE AGENT | AZUMA, ARATA (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-2213309-B1 | CANCER CELL DEATH INDUCER HAVING ACTIVITY OF POTENTIATING ANTI-CANCER AGENT IN CANCER HAVING RESISTANCE AGAINST THE ANTI-CANCER AGENT | MOMOTARO-GENE INC (JP) | 2017-05-10 | — | — | EP | disclosed |
| US-8946173-B2 | Cancer cell death inducing agent having effects of potentiating anticancer drug against anticancer-drug-resistant cancer | MOMOTARO-GENE INC. (JP) | 2015-02-03 | — | — | US | disclosed |
| CN-101918035-B | Cancer cell death inducer having anticancer drug potentiating activity against anticancer drug resistant cancer | MOMOTARO GENE INC | 2013-09-04 | — | — | CN | disclosed |
| EP-2392323-A1 | PROSTATE CANCER PROGRESSION INHIBITOR AND PROGRESSION INHIBITION METHOD | Kyoto University (JP) | 2011-12-07 | — | — | EP | disclosed |
| US-20110287112-A1 | PROSTATE CANCER PROGRESSION INHIBITOR AND PROGRESSION INHIBITION METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110269824-A1 | CANCER CELL DEATH INDUCING AGENT HAVING EFFECTS OF POTENTIATING ANTICANCER DRUG AGAINST ANTICANCER-DRUG-RESISTANT CANCER | MOMOTARO-GENE INC. (JP) | 2011-11-03 | — | — | US | disclosed |
| CN-101918035-A | Cancer cell death inducer having anticancer agent-enhancing activity in cancer resistant to anticancer agent | MOMOTARO GENE INC | 2010-12-15 | — | — | CN | disclosed |
| EP-2213309-A1 | CANCER CELL DEATH INDUCER HAVING ACTIVITY OF POTENTIATING ANTI-CANCER AGENT IN CANCER HAVING RESISTANCE AGAINST THE ANTI-CANCER AGENT | Momotaro-Gene Inc. (JP) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009114658-A2 | ANDROGEN RECEPTOR INACTIVATION CONTRIBUTES TO ANTITUMOR EFFICACY OF CYP17 INHIBITORS IN PROSTATE CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2009-09-17 | — | — | WO | disclosed |
| EP-1186275-A1 | Dental implant and prosthesis | Hermann, Werner (CH) | 2002-03-13 | — | — | EP | disclosed |
| EP-0691963-B1 | HEPOXILIN ANALOGS USEFUL AS ANTI-INFLAMMATORY AGENTS | HSC RES DEV LP (CA) | 1998-07-15 | — | — | EP | disclosed |
| US-5616607-A | TREATS INFLAMMATION, ASTHMA, HYPERTENSION, MIGRAINE AND SEPTIC SHOCK | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 1997-04-01 | — | — | US | disclosed |
| EP-0691963-A1 | HEPOXILIN ANALOGS USEFUL AS ANTI-INFLAMMATORY AGENTS | HSC Research and Development Limited Partnership (CA) | 1996-01-17 | — | — | EP | disclosed |
| WO-1994022848-A1 | HEPOXILIN ANALOGS USEFUL AS ANTI-INFLAMMATORY AGENTS | PACE ASCIAK CECIL R (CA) | 1994-10-13 | — | — | WO | disclosed |
| EP-0581617-A1 | Electronic prostal scale with variable feed belt | PITNEY BOWES INC. (US) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224667-A1 | CANCER CHEMOPREVENTIVE AGENT | TP53, VHL, BRCA1 | TSHR 4478/4885FAAH 4467/4885TRPV1 1910/4885 |
| US-20110287112-A1 | PROSTATE CANCER PROGRESSION INHIBITOR AND PROGRESSION INHIBITION METHOD | ACP3, BPHL, AR | TSHR 4011/4885FAAH 915/4885TRPV1 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.